Top Gap Ups and Downs on Friday: SNAP, GOOGL, INTC and More
Gaps can show signals that something important has happened to the fundamental or the psychology of traders that accompanies this market movement.
EU Panel Backs Approval of Takeda's Colorectal Cancer Drug
Takeda Pharmaceutical (TKD.F) was notified that the European Medicines Agency's Committee for Medicinal Products for Human Use recommended the approval of fruquintinib to treat metastatic colorectal c
Down -5.9% in 4 Weeks, Here's Why Takeda Pharmaceutical Co. (TAK) Looks Ripe for a Turnaround
Takeda Receives Positive CHMP Opinion For Fruquintinib In Previously Treated Metastatic Colorectal Cancer
− If Approved in the European Union, Fruquintinib Will Be the First Novel Targeted Therapy for Metastatic Colorectal Cancer Regardless of Biomarker Status in Over a Decade− Positive Opinion Based on R
Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer
Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC).
Top Gap Ups and Downs on Thursday: META, AZN, CAT and More
Gaps can show signals that something important has happened to the fundamental or the psychology of traders that accompanies this market movement.
20 Fastest Growing Health Tech Companies in the World
Top Gap Ups and Downs on Wednesday: TSLA, TXN, BSX and More
Gaps can show signals that something important has happened to the fundamental or the psychology of traders that accompanies this market movement.
Neurocrine Succeeds in Mid-stage Trial for Takeda-partnered Depression Drug
Neurocrine Biosciences Says Treatment Can Alleviate Several Symptoms Associated With Depressive Disorder
Neurocrine Biosciences Inc (NASDAQ:NBIX) revealed on Tuesday topline data for its Phase 2 SAVITRI study of NBI-1065845 in adult subjects with major depressive disorder (MDD). In 2020, Neurocrine Biosc
TDK, Murata Manufacturing, etc. (additional) Rating
Target Stock Price Change Code | Stock Name | Securities Company | Conventional | After Change |------|-------|-------|<3543>|Komeda HD |SMBC Nikko |3000 yen |<4502>|Takeda Pharmaceutical | Yamato | 4200 yen | 4500 yen |<6268>|Nabtesco | Tokai
Convertible Stock List (Part 1) [Parabolic Signal Convertible Stock List]
○ Purchase conversion stock list market code stock name closing price SAR Tokyo Stock Exchange Prime <2053> Chubu Feed 1173 1080 <2109> DM Mitsui Sugar 3025 2937 <2266> Rokko Butter 1453 1395 <2294> Kakiyasu Main Store 3180 3090 <2590> dyDo
Takeda Pharmaceutical Wins US FDA Approval for Subcutaneous Administration of Crohn's Disease Therapy
Takeda Pharmaceutical (TYO:4502) received the US Food and Drug Administration's approval for the subcutaneous administration of Entyvio, a maintenance therapy for adults with moderate to severe Crohn'
Research and development partnership between Cancer Research Foundation and Takeda Pharmaceutical
Regarding the partnership between the Cancer Research Foundation and Takeda Pharmaceutical on 2024/4/4/22, I would like to inform you that the Cancer Research Foundation (hereafter, the Cancer Research Group) and Takeda Pharmaceutical Co., Ltd. (hereafter, Takeda Pharmaceutical) have now signed an agreement on a development partnership in the cancer field. The Cancer Research Group and Takeda Pharmaceutical will promote global early clinical trials and bridge research (translational research/reverse translational research) based on this agreement
Notice regarding the conclusion of a basic agreement between Takeda Pharmaceuticals, Astellas Pharma, and Sumitomo Mitsui Banking Corporation to incubate drug discovery seeds
Notice regarding the conclusion of a basic agreement to establish a joint venture to incubate Takeda Pharmaceuticals, Astellas Pharma, and Sumitomo Mitsui Bank Drug Discovery Seeds 2024/4/22 Takeda Pharmaceutical Co., Ltd. (Headquarters: Osaka-shi, Osaka; President and CEO: Christophe Weber; hereinafter “Takeda Pharmaceuticals”), Astellas Pharma Co., Ltd. (Headquarters: Chuo-ku, Tokyo; President and CEO: Okamura Naoki, hereinafter “Astellas Pharmaceuticals”), and Sumitomo Mitsui Banking Corporation ( Headquarters: Chiyoda-ku, Tokyo
Top Gap Ups and Downs on Friday: TM, NFLX, HDB and More
Gaps can show signals that something important has happened to the fundamental or the psychology of traders that accompanies this market movement.
Sector Update: Health Care Stocks Steady Pre-Bell Friday
Health care stocks were steady pre-bell Friday, with the Health Care Select Sector SPDR Fund (XLV) inactive and the iShares Biotechnology ETF (IBB) recently down 0.1%. Sanofi (SNY) is reportedly plann
Takeda Pharmaceutical Receives FDA Approval for Single-Dose Injection Crohn's Disease Treatment
Takeda Pharmaceutical (TAK) said Thursday it received US Food and Drug Administration approval for subcutaneous injection of Entyvio as a maintenance therapy in adults with moderately to severely acti
Express News | Reported Earlier, Takeda Announces U.S. FDA Approval Of ENTYVIO Subcutaneous Administration For Maintenance Therapy In Moderately To Severely Active Crohn's Disease
Systems Design, Adsol Nissin, etc.
<1383>Belgium Earth Co., Ltd. Yamaguchi Kazuhiko Stock Ownership Ratio 13.38% → 12.96% Reporting Obligation Date 2024/04/15 <2721>J-Holdings Co., Ltd. Nakatani Masakazu Stock Ownership Ratio 10.70% → 9.30% Reporting Obligation Date 2024/04/10 <3766>Systems Design Co., Ltd. Hikari Communication Co., Ltd. Stock Ownership Ratio 10.42% → 11.42% Reporting Obligation Date
No Data